Masters of Longevity - The Pulse

Nature - Biotechnology21 Jul 2026
Catalytic profiling of extracellular vesicles maps altered cancer metabolism (Nature - Biotechnology)

Catalytic profiling of extracellular vesicles maps altered cancer metabolism

Covers a programmable nanohybrid platform that profiles extracellular vesicle metabolites in native biofluids to map tumour metabolic changes and prognosis.

Key takeaways
  • Additional data that support the findings of this study are available from the corresponding author upon request.
  • View all journals Current technologies for measuring cancer metabolism have limited clinical utility.
  • Termed atomically configured catalytic hybrids for profiling extracellular vesicle metabolites (ACTIVE).
Frontiers - Health21 Jul 2026
AIDurable response to ALK inhibition in low-allele-frequency SPTBN1–ALK–rearranged gastric cancer followed by lineage plasticity–mediated resistance: a case repor

Durable response to ALK inhibition in low-allele-frequency SPTBN1–ALK–rearranged gastric cancer followed by lineage plasticity–mediated resistance: a case report

A case report describing durable tumor shrinkage from ALK inhibition in gastric cancer with a low-frequency SPTBN1–ALK fusion and later lineage-driven resistance.

Key takeaways
  • Tumor was negative for HER2 amplification, microsatellite instability, and PD-L1 expression.
  • Accompanied by expansion of TP53-mutant alleles and acquisition of additional genomic alterations.
  • Subsequent histologic transformation to small-cell neuroendocrine carcinoma was observed.
MoL Event Pick
Longevity Wellness Expo 2026 (Toronto, Canada)

Longevity Wellness Expo 2026

2. OCT 2026 - 4. OCT 2026 - Toronto, CanadaExpo

Toronto expo and conference focused on longevity, wellness, biohacking, health optimization and healthy aging products and services.

Nature - Biotechnology21 Jul 2026
Individualized antisense oligonucleotides for SCN2A-related developmental epileptic encephalopathy (Nature - Biotechnology)

Individualized antisense oligonucleotides for SCN2A-related developmental epileptic encephalopathy

Reports personalized allele-selective antisense oligonucleotide treatment in two patients with SCN2A-related developmental and epileptic encephalopathy, showing individualized clinical outcomes.

Key takeaways
  • Two n=1 individualized allele-selective ASO treatments reduced seizures by 26% and 90% respectively.
  • Haplotype phasing found 16% of infants with SCN2A-related disorder carry compatible SNPs for allele-selective ASOs.
  • Both ASOs were well tolerated with no ASO-related serious adverse events reported.
Frontiers - Health21 Jul 2026
AILysophosphatidylcholine and lysophosphatidic acid as key messengers in atherosclerosis: from a lipid-inflammation vicious cycle to therapeutic translation (Fron

Lysophosphatidylcholine and lysophosphatidic acid as key messengers in atherosclerosis: from a lipid-inflammation vicious cycle to therapeutic translation

A review synthesizing mechanistic and spatial metabolomics evidence that specific lysophospholipids link lipid dysfunction and inflammation in atherosclerosis.

Key takeaways
  • These LPLs activate specific G protein-coupled receptors (GPCRs).
  • Accumulating evidence indicates that LPLs are not passive byproducts of atherosclerotic disease.
  • Using matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI).